The healthcare and technology sectors are experiencing unprecedented growth as companies push the boundaries of innovation to address critical global challenges. From revolutionary treatments for cardiovascular disease to AI-powered tools and cutting-edge medical devices, these advancements are reshaping industries and creating significant opportunities for investors. Market leaders and emerging innovators alike are driving transformative change, paving the way for a healthier, more connected future.

Stocks struggled for direction, but the trend before tech earnings is still bullish. Nevertheless, investors should expect volatility ahead of the election.

Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results align with the trend.

These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025.

Shares of Abbott Laboratories (NYSE: ABT) traded at a new 52-week high today and are currently trading at $119.69. So far today, approximately 2.44M shares have been exchanged, as compared to an average 30-day volume of 5.95M shares.

Medtronic is a leading global medical device maker in the medical sector. Its innovative and critical medical device portfolio addresses chronic diseases

Medtronic's Q1 FY2025 results were driven by its diabetes products, and new offerings in development or pending FDA approval could fuel future performance.

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Intuitive Surgical is an AI stock that you can buy and hold forever. Its business is health care; it makes profits, and health care is growing

Abbott's reliable dividend is more reliable than ever and is expected to continue growing at a high-single to low-double-digit CAGR.

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology firm at the forefront of developing and marketing rapid, intelligent, cutting-edge, and non-intrusive drug testing and health screening solutions. The company is actively involved in commercializing its smart fingerprinting device for drug testing, which has gained rapid traction in the healthcare market segment.

Medical device maker Boston Scientific Co. defies Medtech slowdown and delivers a solid Q1 2024 earnings report, and raises 2024 outlook.

PALM BEACH, Fla., May 21, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The sports nutrition market is experiencing significant growth due to the evolving preferences of consumers seeking healthier and tailored nutritional options and for maintaining muscle growth during weight loss. The sports nutrition market is experiencing robust growth due to increasing consumer awareness about the importance of fitness and healthy lifestyles. Industry players are emphasizing innovation in product development to meet the rising demand for personalized nutrition solutions. Key growth drivers include a surge in health-conscious consumers, a growing fitness culture, and a rising interest in sports activities. The market is witnessing a shift toward natural and organic ingredients, with companies striving to provide clean-label products that align with the preferences of a discerning consumer base. A report from Allied Market Research said that the global sports nutrition market generated $43,651.8 million in 2023 and is anticipated to generate $78,427.5 million by 2032, witnessing a CAGR of 6.7% from 2023 to 2032. The report said: “Despite the positive momentum, regulatory complexities pose challenges, necessitating significant investments in research and development for compliance. However, these challenges also open doors for businesses to distinguish themselves through transparent, high-quality offerings. The expanding reach of e-commerce further unlocks opportunities, allowing companies to tap into a broader consumer base and capitalize on the increasing trend of online health and wellness purchases.” Active biotech and pharma companies in the markets this week include Promino Nutritional Sciences Inc. (OTCPK: MUSLF) (CSE: MUSL), Abbott (NYSE: ABT), Celsius Holdings, Inc. (NASDAQ: CELH), Monster Beverage Corporation (NASDAQ: MNST), BellRing Brands, Inc. (NYSE: BRBR).

Abbott Laboratories had a steady quarter, producing growth, better-than-expected earnings, and raising the guidance. Analysts see the stock moving higher.

Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely.

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People

For decades, opioids have been the go-to medication for managing post-operative and other types of pain. However, the tide is turning as the devastating consequences of opioid addiction become increasingly clear. Athletes, known for pushing their bodies to the limit, are at the forefront of this shift, seeking out innovative, non-opioid solutions to manage pain after surgery and expedite healing. Their experiences are raising public awareness – and investor attention – about alternative treatment options and paving the way for a future where powerful painkillers are not the only answer.

A strong earnings report backed by raised guidance adds to the allure of Medtronic stock, which is already a Dividend Aristocrat in the healthcare sector

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

MedTech stocks have had plenty of reason to rally over the last year but haven't. That is about to change with growth accelerating in 2024 and 2025.

Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact.

Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech.